KUS187

KUS187 protects neuronally differentiated PC12 cells from MPP⁺-induced cell death^[1].
KUS187 (25 μM; 24 h) protects primary midbrain dopaminergic neurons from MPP⁺-induced death and neurite atrophy^[1].
KUS187 (30-1000 nM; 20 min) inhibits recombinant human VCP ATPase activity with an IC₅₀ of 186 nM^[2].
KUS187 (100 nM-1 mM; 20 min) decreased total soluble ATPase activity in lysates of neuronally differentiated PC12 cells, by approximately 20% at 100 nM and approximately 40% at 1 mM^[2].
KUS187 (20 μM; 41 h) protects HeLa cells from Glucose-induced cell death^[2].
KUS187 (20 μM; 41 h) protects HeLa cells from Tunicamycin-induced cell death^[2].
KUS187 (50 μM; 5 h) prevents Tunicamycin-induced laminin c1 aggregation in HeLa cells^[2].
KUS187 helps maintain cytoplasmic and mitochondrial ATP levels in PC12 cells exposed to MPP^+[1].
KUS187 (50 μM; 24 h) preserves mitochondrial morphology, neurite mitochondrial length, and mitochondrial membrane potential in PC12 cells exposed to MPP⁺, but does not increase mitochondrial mass or reduce ROS^[1].
KUS187 (50 μM; 5 h) inhibits Tunicamycin-induced CHOP and Grp78 expression and restores Akt phosphorylation at Ser473 in HeLa cells^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.